Beran et al[42] found that women with BRCA1/2 mutations (n = 117) reported significantly higher depressive symptoms (measured using the Center for Epidemiologic Studies Depression Scale) at 1 and 6 months after receiving the results. Here, BRCA1 is linked to depressive symptom measurement.